New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Intellia Therapeutics, Inc. (NTLA) vs Rapport Therapeutics, Inc. (RAPP)
- Intellia Therapeutics, Inc. NTLA 10.10 +5.76%
- Rapport Therapeutics, Inc. RAPP 23.35 −1.14%
Intellia Therapeutics, Inc. and Rapport Therapeutics, Inc. are both Biotechnology companies. Intellia Therapeutics, Inc. and Rapport Therapeutics, Inc. are of similar size ($1.4B and $1.3B). Rapport Therapeutics, Inc. has the higher net margin (0.00% vs −805.8%) and the higher return on invested capital (0.00% vs −195.3%). Across the 12 metrics below, Rapport Therapeutics, Inc. leads on 9 and Intellia Therapeutics, Inc. on 3.
Valuation
Profitability
| Metric | NTLA | RAPP | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | — | 70.18% |
| Operating margin | (821.24%) | 0.00% | 0.00% |
| Net margin | (805.75%) | 0.00% | 0.00% |
| Free cash flow margin | (676.38%) | 0.00% | 0.00% |
| Return on equity | (62.60%) | (33.33%) | (51.58%) |
| Return on assets | (46.63%) | (31.55%) | (45.91%) |
| Return on invested capital | (195.32%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack